{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:24:18Z","timestamp":1790871858503,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing use of immune checkpoint inhibitors (ICIs) has resulted in a growing population of long-term survivors (LTS). However, the long-term psychosocial and quality of life (QoL) outcomes in these patients remain underexplored. This study aimed to evaluate QoL, psychological morbidity, fear of cancer progression (FoP), and functional outcomes in cancer patients treated with ICIs for at least six months without disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional, multicenter study included 346 adult cancer patients from 17 tertiary oncology centers in T\u00fcrkiye. Participants had received ICIs for \u22656 months in (neo)adjuvant or metastatic settings. Standardized questionnaires assessed QoL, psychological distress, FoP, immune-related adverse events (irAEs), and work status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the cohort was 62 years (IQR: 53\u201369). Average survivor QoL was comparable to the Turkish general population; but 119 (34.5%) survivors had poor QoL. Clinically relevant symptoms of depression and anxiety were present in 24.3% and 20.8% of patients, respectively, while 48% reported FoP. The overall return-to-work rate among patients initially employed was 50.9%, with 72.7% returning within the first year. Depression, anxiety, and FoP were negatively correlated with all QoL domains. All grade irAEs were common (53.8%) but not significantly associated with worse QoL (p=0.149).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study represents one of the largest cohorts to date evaluating survivorship issues among LTS treated with ICIs. Among patients receiving ICIs for at least six months, nearly one-third experienced impaired QoL, primarily driven by psychological distress and FoP. Further research is needed to address survivorship care in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1693295","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:40:19Z","timestamp":1765348819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Taha Koray","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Atalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahadir","family":"Koylu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydin","family":"Acarbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akgun","family":"Karakok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevat Ilteris","family":"Kikili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6rkem","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Emin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selahattin","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Deliktas Onur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba Ugur","family":"Tuzcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa Can","family":"Efil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime Sinem","family":"Ardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azer","family":"Gokmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil Goksel","family":"Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet K\u00fcrsad","family":"Disli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Tunbekici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Goker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevlude","family":"Inanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muslih","family":"Urun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatime Arzu","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Oguz","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Sutcuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozturk","family":"Ates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulay","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atila","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Alev","family":"Turker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3456","article-title":"Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis","volume":"10","author":"Villacampa","year":"2024","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-023-01507-w","article-title":"Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review","volume":"19","author":"G\u00fcven","year":"2025","journal-title":"J Cancer Surviv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5967","article-title":"Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors","volume":"12","author":"Looman","year":"2023","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4086","article-title":"Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review","volume":"10","author":"Malone","year":"2021","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12955-021-01816-7","article-title":"The effect of fear of progression on quality of life among breast cancer patients: the mediating role of social support","volume":"19","author":"Ban","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70561","article-title":"Fear of cancer recurrence and associated factors in lymphoma survivors and their family caregivers: A cross-sectional study","volume":"14","author":"Sahin","year":"2025","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-05168-3","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2165449","article-title":"Quality of life and mental health in real-world patients with resected stage III\/IV melanoma receiving adjuvant immunotherapy","volume":"62","author":"Pedersen","year":"2023","journal-title":"Acta Oncologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35204","article-title":"Anxiety and depression in cancer patients and survivors in the context of restrictions in contact and oncological care during the COVID-19 pandemic","volume":"156","author":"Doege","year":"2025","journal-title":"Int J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1017\/s147895152200116x","article-title":"Quality of life, anxiety, depression, and distress in patients with advanced and metastatic lung cancer","volume":"21","author":"Gonzalez-Ling","year":"2023","journal-title":"Palliat Support Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J immunother cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e011168","DOI":"10.1136\/jitc-2024-011168","article-title":"Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment","volume":"13","author":"Wellington","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00296-0","article-title":"The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy","author":"Kaasa","year":"1995","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1365-2354.2007.00827.x","article-title":"Understanding the reliability and validity of the EORTC QLQ-C30 in Turkish cancer patients","volume":"17","author":"Cankurtaran","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2015.04.006","article-title":"Assessing anxiety and depression with respect to the quality of life in cancer inpatients receiving palliative care","volume":"19","author":"Bu\u017egov\u00e1","year":"2015","journal-title":"Eur J Oncol Nurs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s40359-025-02650-y","article-title":"Assessment of the fear of progression in Turkish cancer patients: a validation and reliability study fear of progression questionnaire short form","volume":"13","author":"\u015eahin","year":"2025","journal-title":"BMC Psychol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/prbm.S231577","article-title":"Spotlight on the fear of cancer recurrence inventory (FCRI)","volume":"13","author":"Smith","year":"2020","journal-title":"Psychol Res Behav Manage"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-015-0424-4","article-title":"Screening and comorbidity of clinical levels of fear of cancer recurrence","volume":"9","author":"Simard","year":"2015","journal-title":"J Cancer Surviv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/07347332.2020.1836547","article-title":"The experience of financial toxicity among advanced melanoma patients treated with immunotherapy","volume":"39","author":"Thom","year":"2021","journal-title":"J Psychosoc Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers13010103","article-title":"Use of a cancer registry to evaluate patient-reported outcomes of immune checkpoint inhibitors","volume":"13","author":"Jim","year":"2021","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04818-w","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O\u2019Reilly","year":"2020","journal-title":"Support Care Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70244-4","article-title":"Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis","volume":"14","author":"Mitchell","year":"2013","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3975-2","article-title":"Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service","volume":"26","author":"Thewes","year":"2018","journal-title":"Support Care Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e3182813a17","article-title":"The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors","volume":"37","author":"Custers","year":"2014","journal-title":"Cancer nursing"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2016.1150607","article-title":"Fear of cancer recurrence in prostate cancer survivors","volume":"55","author":"van de Wal","year":"2016","journal-title":"Acta oncologica"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115568","article-title":"Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors","volume":"225","author":"\u00d6zkan","year":"2025","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-025-01825-1","article-title":"Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients","author":"Lijnsvelt","year":"2025","journal-title":"J Cancer Surviv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0217","article-title":"Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:40:21Z","timestamp":1765348821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1693295"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1693295","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1693295"}}